The pDx platform uses smartphone cameras to capture digital biomarkers and deliver real-time data to clinicians via secure dashboard.
Digital medicine company electronRx has developed a mobile application that allows patients with chronic respiratory diseases to monitor their lung function at home using smartphones, tablets, or laptops.
electronRx announced it will launch the pDx app at HLTH 2025 in Las Vegas Oct 19-22. The platform is designed to help clinicians remotely assess cardiopulmonary function, track disease progression, and adjust treatment protocols for conditions including asthma, COPD, interstitial lung disease, and pulmonary hypertension.
The technology uses device camera sensors to capture and measure blood flow biomechanics, generating digital biomarkers that translate into clinical metrics such as heart rate, respiratory rate, and tidal volume. Healthcare providers receive this data in real time through a secure clinical dashboard.
“The platform’s scalable architecture supports integration into existing care pathways, allowing for proactive intervention and reduced reliance on in-person visits,” says Dr Bipin Patel, chief executive officer and founder of electronRx, in a release. “By facilitating continuous monitoring, pDx helps clinicians personalize care while improving patient adherence and reducing healthcare burden.”
The pDx app expands upon the company’s existing purpleDx technology by adding tailored questionnaires and providing access to detailed results for both patients and clinicians. While the original technology was limited to mobile phones, pDx can be accessed on any device with a screen.
Addressing Global Health Burden
Chronic respiratory diseases represent the third leading cause of death globally, according to the company. The pDx platform aims to reduce the need for frequent hospital visits while helping healthcare systems streamline delivery and reduce resource strain.
The app includes a complementary clinical dashboard designed to enhance detection, monitoring, and treatment of chronic respiratory conditions. The technology is engineered to medical-grade standards and enables dynamic adjustment of treatment plans to optimize drug efficacy.
electronRx will demonstrate the pDx technology at booth 4118 during HLTH 2025. The Cambridge, UK-based company specializes in digital medicine and biomarker development focused on pulmonary innovation.
Photo caption: pDx app
Photo credit: electronRx
